Ac-SDKP comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
== Differentiation of conditions == Clinical attachment loss (CAL) is a critical parameter in periodontal diagnosis, as it reflects true periodontal tissue destruction. However, increased probing depth does not always indicate attachment loss. Conditions such as pseudopockets and gingival enlargement can mimic periodontal pockets clinically, leading to diagnostic confusion. This part of the article discusses CAL in comparison with pseudopockets and gingival enlargement, highlighting their pathogenesis, clinical features, and diagnostic significance.
==== Chromium ==== Clinical and experimental studies have reported antidepressant activity of chromium particularly in atypical depression, characterized by increased appetite and carbohydrate craving.
While balloons are perhaps the best-known use of helium, they are a minor part of all helium use. Helium is used for many purposes that require some of its unique properties, such as its low boiling point, low density, low solubility, high thermal conductivity, or inertness. Of the 2014 world helium total production of about 32 million kg (180 million standard cubic meters) of helium per year, the largest use (about 32% of the total in 2014) is in cryogenic applications, most of which involves cooling the superconducting magnets in medical MRI scanners and NMR spectrometers. Other major uses were pressurizing and purging systems, welding, maintenance of controlled atmospheres, and leak detection. Other uses by category were relatively minor fractions.
Pressure can interrupt or arrest the microcirculatory environment of the nerve starting a pathophysiological cascade. As the heart beats, it pushes blood through arteries/arterioles/capillaries. Blood also travels through veins though more passively via valves and the assistance of muscles to squeeze veins. If there is localized pressure high enough, it can interrupt the normal flow of blood. For compression to affect nerve function, pressure needs to be applied non-uniformly. For example, frogs can survive in isolated pressure chambers at high pressures but much lower local compression can block conduction of the nerve. Scuba divers can dive to tens of meters of water depth and will not experience any form of nerve compression, but the same pressure divers experience under 1 meter of water (pressure under 1m of water is 10k Pascal ~ 80mmHg) applied locally can completely arrest nerve function. Compression is especially likely in anatomic tunnels or fibro-osseous spaces where there may be a conflict with the amount of free space available and the volume of the contents. If the tunnel narrows or if the contents of the tunnel expand, there will be an increase in pressure. Examples of tunnels are the carpal tunnel, tarsal tunnel, and cubital tunnel. Sometimes compression occurs in areas that are not considered tunnels and where a nerve passes between two mechanically stiffer tissue types that can squeeze or pinch the soft nerve.
Sources: en.wikipedia.org
9 May The New York Times carried a front page story titled "Raids in Cambodia By U.S. Unprotested" which was the first report of the secret Operation Menu bombing of Cambodia. The story would lead the Nixon Administration to try to uncover sources within the government who contributed to the article, leading to the wiretapping of journalists and eventually to the Watergate scandal.
=== Endoplasmic reticulum === The discovery of an animal cell AMPylase, followed by the discovery of its ER localisation and that BiP is a prominent substrate for its activity were important breakthroughs. BiP (also known as Grp78) had long been known to undergo an inactivating post-translational modification, but its nature remained elusive. Widely assumed to be ADP-ribosylation, it turns out to be FICD-mediated AMPylation, as inactivating the FICD gene in cells abolished all measurable post-translational modification of BiP. BiP is an ER-localised protein chaperone whose activity is tightly regulated at the transcriptional level via a gene-expression program known as the Unfolded Protein Response (UPR). The UPR is a homeostatic process that couples the transcription rate of BiP (and many other proteins) to the burden of unfolded proteins in the ER (so-called ER stress) to help maintain ER proteostasis. AMPylation adds another rapid post-translational layer of control of BiP's activity, as modification of Thr518 of BiP's substrate-binding domain with an AMP locks the chaperone into an inactive conformation. This modification is selectively deployed as ER stress wanes, to inactivate surplus BiP. However, as ER stress rises again, the same enzyme, FICD, catalyses the opposite reaction, BiP de-AMPylation. An understanding of the structural basis of BiP AMPylation and de-AMPylation is gradually emerging, as are clues to the allostery that might regulate the switch in FICD's activity but important details of this process as it occurs in cells remain to be discovered.
=== Independent investigations === In June 2021, the NIH announced that a set of sequence data had been removed from the Sequence Read Archive (SRA) in June 2020. The removal was performed according to standard practice at the request of the investigators who owned the rights to the sequences, with the investigators' rationale that the sequences would be submitted to another database. The investigators subsequently published a paper in an academic journal the same month they were removed from the NIH database which described the sequences in detail and discussed their evolutionary relationship to other sequences, but did not include the raw data. Virologist David Robertson said that it was difficult to conclude it was a cover-up rather than the more likely explanation: a mundane deletion of data without malfeasance. The missing genetic sequence data was restored in a correction published 29 July 2021 after it was stated to be a copy-edit error. In September 2024, a study published in Cell found genetic evidence that COVID-19 may have originated from the illegal trade of infected raccoon dogs in Wuhan, China, supporting the zoonotic transmission scenario. Swabs taken from the Huanan Seafood Wholesale Market in January 2020, which tested positive for coronavirus, contained large amounts of genetic material from raccoon dogs.
Leo is the franchise." In a 2016 analysis of his career trajectory, Stacey Wilson Hunt of New York magazine opined that DiCaprio, unlike most of his contemporaries, had not starred in a bad film in the previous ten years. Of his success, DiCaprio says, "My attitude is the same as when I started. I feel very connected to that fifteen-year-old kid who got his first movie." DiCaprio has named Robert De Niro and James Dean as two of his favorite and most influential actors, stating "There were a lot of great actors I really fell in love with, but if I were to pick two, from different generations, it would be De Niro and James Dean". When asked about a performance that stayed with him the most, DiCaprio responded, "I remember being incredibly moved by Jimmy Dean, in East of Eden. There was something so raw and powerful about that performance. His vulnerability [...] his confusion about his entire history, his identity, his desperation to be loved. That performance just broke my heart."
=== Discrete pathophysiology and CTS === Hereditary neuropathy with susceptibility to pressure palsies is a genetic condition that appears to increase the probability of developing CTS. Heterozygous mutations in the gene SH3TC2, associated with Charcot-Marie-Tooth, may confer susceptibility to neuropathy, including CTS. Association between common benign tumors such as lipomas, ganglion, and vascular malformation should be handled with care. Such tumors are very common and are more likely to compress the median nerve. Similarly, the association between transthyretin amyloidosis-associated polyneuropathy and carpal tunnel syndrome is under investigation. Prior carpal tunnel release is often noted in individuals who later present with transthyretin amyloid-associated cardiomyopathy. There is consideration that bilateral carpal tunnel syndrome could be a reason to consider amyloidosis, timely diagnosis of which could improve heart health. Amyloidosis is rare, even among people with carpal tunnel syndrome (0.55% incidence within 10 years of carpal tunnel release). In the absence of other factors associated with a notable probability of amyloidosis, it is not clear that biopsy at the time of carpal tunnel release has a suitable balance between potential harms and potential benefits. Other specific pathophysiologies that can cause CTS via pressure include:
Sources: en.wikipedia.org
== D == Dakin reaction (AKA Dakin oxidation) Dakin–West reaction Danheiser annulation Danheiser benzannulation Darapsky degradation Darzens condensation, Darzens–Claisen reaction, Glycidic ester condensation Darzens halogenation Darzens synthesis of unsaturated ketones Darzens tetralin synthesis Davis' reagent, Davis oxidation Davis–Beirut reaction De Kimpe aziridine synthesis Dehydration reaction Dehydrogenation Delépine reaction DeMayo reaction Demjanov rearrangement Demjanow desamination Dess–Martin oxidation Diazoalkane 1,3-dipolar cycloaddition Diazotisation DIBAL-H selective reduction Dieckmann condensation Dieckmann reaction Diels–Alder reaction Diels–Reese reaction Dienol–benzene rearrangement Dienone–phenol rearrangement Dimroth rearrangement Di-π-methane rearrangement Directed ortho metalation Doebner modification Doebner reaction Doebner–Miller reaction, Beyer method for quinolines Doering–LaFlamme carbon chain extension Dötz reaction Dowd–Beckwith ring expansion reaction Duff reaction Dutt–Wormall reaction Dyotropic reaction
== External links == SR-17018 - Isomer Design r/SR17018 - Reddit SR-17018 Guide: How to Take It and Some Simplified Science - Reddit SR-17018 Education and Discussion - Facebook Groups - Facebook SR-17018 Harm Reduction (sr17018.org) Save SR-17018 (stop-sr17-ban.com) SR-17018 - Wikipedia Pageviews Analysis
Flucytosine: The toxicity of flucytosine is increased and allows for a lower dose of amphotericin B. Amphotericin B may also facilitate entry of flucytosine into the fungal cell by interfering with the permeability of the fungal cell membrane. Diuretics or cisplatin: Increased renal toxicity and increased risk of hypokalemia Corticosteroids: Increased risk of hypokalemia Imidazole antifungals: Amphotericin B may antagonize the activity of ketoconazole and miconazole. The clinical significance of this interaction is unknown. Neuromuscular-blocking agents: Amphotericin B–induced hypokalemia may potentiate the effects of certain paralytic agents. Foscarnet, ganciclovir, tenofovir, adefovir: The risk of hematological and kidney side effects of amphotericin B is increased Zidovudine: Increased the risk of kidney and hematological toxicity. Other nephrotoxic drugs (such as aminoglycosides): Increased risk of serious renal damage Cytostatic drugs: Increased risk of kidney damage, low blood pressure, and airway spasms Transfusion of leukocytes: There is a risk that pulmonary (lung) damage may occur. Space the intervals between the application of amphotericin B and the transfusion, and monitor pulmonary function
Each exists in the form of a hydrogen phosphate anion ([HPO4]2−), dissociating to contribute 2H+ overall Each liberates an oxygen atom when it binds to an adenosine diphosphate (ADP) molecule, contributing 2 O overall Charges are balanced by the difference between ADP and ATP. In the cellular environment, all three hydroxyl groups of ADP dissociate into −O− and H+, giving ADP3−, and this ion tends to exist in an ionic bond with Mg2+, giving ADPMg−. ATP behaves identically except that it has four hydroxyl groups, giving ATPMg3−. When these differences along with the true charges on the two phosphate groups are considered together, the net charges of −4 on each side are balanced. In high-oxygen (aerobic) conditions, eukaryotic cells can continue from glycolysis to metabolise the pyruvate through the citric acid cycle or the electron transport chain to produce significantly more ATP. Importantly, under low-oxygen (anaerobic) conditions, glycolysis is the only biochemical pathway in eukaryotes that can generate ATP, and, for many anaerobic respiring organisms the most important producer of ATP. Therefore, many organisms have evolved fermentation pathways to recycle NAD+ to continue glycolysis to produce ATP for survival. These pathways include ethanol fermentation and lactic acid fermentation.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.